Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Grundmann, H., Aires-de-Sousa, M., Boyce, J. & Tiemersma, E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368, 874–885 (2006).
Anti-tuberculosis drug resistance in the world. Fourth global report. Vol. 394 The WHO/IUATLD Global Project on Antituberculosis Drug Resistance Surveillance, World Health Organization: Geneva WHO/HTM/TB 10–12 (2008).
Alexander, P. E. & De, P. The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada. Can. J. Infect. Dis. Med. Microbiol. 18, 289–291 (2007).
Panchal, R. G. et al. Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains. Antimicrob. Agents Chemother. 53, 4283–4291 (2009).
Opperman, T. J. et al. Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR. Bioorg. Med. Chem. 18, 2123–2130 (2010).
Butler, M. M. et al. Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates. Antimicrob. Agents Chemother. 54, 3974–3977 (2010).
Jeon, C. Y. et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin. Infect. Dis. 46, 42–49 (2008).
Clinical and Laboratory Standards Institute (CLSI).. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A7; Approved standard-Seventh Edition., Clinical and Laboratory Standards Institute: Wayne, PA, (2006).
Acknowledgements
This project has been funded in part by HDTRA1-06-C-0042 to Microbiotix Inc. and by Defense Threat Reduction Agency (DTRA) to RGP and SB, and with federal funds from the National Cancer Institute, National Institutes of Health (under contract N01-CO-12400) and in part by the Intramural Research Program of the NIH, NIAID. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government. This research was supported in part by the Developmental Therapeutics Program in the Division of Cancer Treatment and Diagnosis of the National Cancer Institute. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the US Army.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Panchal, R., Lane, D., Boshoff, H. et al. Bis-imidazolinylindoles are active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Mycobacterium tuberculosis. J Antibiot 66, 47–49 (2013). https://doi.org/10.1038/ja.2012.93
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2012.93
